Omega-3 Fatty Acid Biomarkers and Incident Atrial Fibrillation
Frank Qian,Nathan Tintle,Paul N Jensen,Rozenn N Lemaitre,Fumiaki Imamura,Tobias Rudholm Feldreich,Sarah Oppeneer Nomura,Weihua Guan,Federica Laguzzi,Eunjung Kim,Jyrki K Virtanen,Marinka Steur,Christian S Bork,Yoichiro Hirakawa,Michelle L O'Donoghue,Aleix Sala-Vila,Andres V Ardisson Korat,Qi Sun,Eric B Rimm,Bruce M Psaty,Susan R Heckbert,Nita G Forouhi,Nicholas J Wareham,Matti Marklund,Ulf Risérus,Lars Lind,Johan Ärnlöv,Parveen Garg,Michael Y Tsai,James Pankow,Jeffrey R Misialek,Bruna Gigante,Karin Leander,Julie A Pester,Christine M Albert,Maryam Kavousi,Arfan Ikram,Trudy Voortman,Erik B Schmidt,Toshiharu Ninomiya,David A Morrow,Antoni Bayés-Genís,James H O'Keefe,Kwok Leung Ong,Jason H Y Wu,Dariush Mozaffarian,William S Harris,David S Siscovick,Fatty Acids and Outcomes Research Consortium (FORCE)
DOI: https://doi.org/10.1016/j.jacc.2023.05.024
2023-07-25
Abstract:Background: The relationship between omega-3 fatty acids and atrial fibrillation (AF) remains controversial. Objectives: This study aimed to determine the prospective associations of blood or adipose tissue levels of eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA) with incident AF. Methods: We used participant-level data from a global consortium of 17 prospective cohort studies, each with baseline data on blood or adipose tissue omega-3 fatty acid levels and AF outcomes. Each participating study conducted a de novo analyses using a prespecified analytical plan with harmonized definitions for exposures, outcome, covariates, and subgroups. Associations were pooled using inverse-variance weighted meta-analysis. Results: Among 54,799 participants from 17 cohorts, 7,720 incident cases of AF were ascertained after a median 13.3 years of follow-up. In multivariable analysis, EPA levels were not associated with incident AF, HR per interquintile range (ie, the difference between the 90th and 10th percentiles) was 1.00 (95% CI: 0.95-1.05). HRs for higher levels of DPA, DHA, and EPA+DHA, were 0.89 (95% CI: 0.83-0.95), 0.90 (95% CI: 0.85-0.96), and 0.93 (95% CI: 0.87-0.99), respectively. Conclusions: In vivo levels of omega-3 fatty acids including EPA, DPA, DHA, and EPA+DHA were not associated with increased risk of incident AF. Our data suggest the safety of habitual dietary intakes of omega-3 fatty acids with respect to AF risk. Coupled with the known benefits of these fatty acids in the prevention of adverse coronary events, our study suggests that current dietary guidelines recommending fish/omega-3 fatty acid consumption can be maintained.